The National Institute for Health Research (NIHR) has today released research results showing that the number of open studies at King’s has increased by six percent this year to 352 from 333 in 2016/17. More open studies means more opportunities for patients to participate in research studies. The number of open life science industry studies also increased by nine percent to 96 from 88.
Dr Kosh Agarwal, Consultant Hepatologist at King’s and Clinical Director of the NIHR Clinical Research Network South London, said: “More open life science industry studies makes more cutting edge treatments available to patients at King’s.
“The life science industry is pioneering treatments that will soon become standard practice in the NHS and supporting that work through offering potentially better treatments to patients is a win-win. In addition, the research is making the UK a global centre for healthcare research and so attracting more research and making more new treatments available to patients.”
Dr Jonathan Sheffield OBE, Chief Executive Officer of the NIHR Clinical Research Network (CRN) said: “By taking part in life sciences industry studies, patients are participating in new and innovative forms of treatment which will provide evidence for future improved care for all patients. The knowledge gained could provide the evidence to license new treatments in the NHS securing healthy lives for future generations.
“Partnerships between the NHS and the life sciences industry bring a range of benefits to the healthcare sector - giving trusts access to new treatments and funding for health research, while also boosting the wider economy each year through the development of cutting edge medical innovations.”